Astal Laboratories Ltd vs Bafna Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Astal Laboratories Ltd is ₹ 62.13 as of 30 Apr 15:30 . The P/E Ratio of Astal Laboratories Ltd changed from 437.5 on March 2021 to 8.4 on March 2025 . This represents a CAGR of -54.64% over 5 yearsThe P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 years The Market Cap of Astal Laboratories Ltd changed from ₹ 3.47 crore on March 2021 to ₹ 74.72 crore on March 2025 . This represents a CAGR of 84.77% over 5 yearsThe Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 years The revenue of Astal Laboratories Ltd for the Dec '25 is ₹ 52.27 crore as compare to the Sep '25 revenue of ₹ 37.55 crore. This represent the growth of 39.2% The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The ebitda of Astal Laboratories Ltd for the Dec '25 is ₹ 3.59 crore as compare to the Sep '25 ebitda of ₹ 3.9 crore. This represent the decline of -7.95% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The net profit of Astal Laboratories Ltd changed from ₹ 1.69 crore to ₹ 2.36 crore over 7 quarters. This represents a CAGR of 21.02% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Astal Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astal Laboratories Ltd

Astal Laboratories Limited was formerly incorporated as a public company limited by shares on August 03, 1993 in the name of Macro International Limited.
The Company was taken over under SEBI takeover guidelines in 2022 and the main objects of the Company was changed to 'Manufacture and Sales of Pharmaceutical Intermediates and Bulk Drugs'.
Subsequently the name of the Company was changed to Astal Laboratories Limited in May, 2024.
The Company is now a subsidiary of Aceso Research Labs LLP. The Company was promoted by the Kanpur based business house of Parasrampurias.
The Company set up a departmental store at Plaza Kalpana, Birhana Road, Kanpur, offering products such as readymade garments, electronic items, leather items, stationery, books, fast food centre etc. During 1996-97, the departmental store project succeeded, only Saree Division and Archies Card Division was in operation.

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

FAQs for the comparison of Astal Laboratories Ltd and Bafna Pharmaceuticals Ltd

Which company has a larger market capitalization, Astal Laboratories Ltd or Bafna Pharmaceuticals Ltd?

Market cap of Astal Laboratories Ltd is 262 Cr while Market cap of Bafna Pharmaceuticals Ltd is 321 Cr

What are the key factors driving the stock performance of Astal Laboratories Ltd and Bafna Pharmaceuticals Ltd?

The stock performance of Astal Laboratories Ltd and Bafna Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astal Laboratories Ltd and Bafna Pharmaceuticals Ltd?

As of May 3, 2026, the Astal Laboratories Ltd stock price is INR ₹62.13. On the other hand, Bafna Pharmaceuticals Ltd stock price is INR ₹135.7.

How do dividend payouts of Astal Laboratories Ltd and Bafna Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astal Laboratories Ltd and Bafna Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.